Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Advanced Medical Solutions Group EV-to-EBIT?
Advanced Medical Solutions GroupCHIX:AMSL 92 EV-to-EBIT is 29.75 as of Jul. 19, 2026, which is 24% above its 10-year median of 24.05. GuruFocus rates CHIX:AMSL with a GF Score™ of 92/100 and a GF Value™ of £3.72 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 73.33% on this metric.
The historical rank and industry rank for Advanced Medical Solutions Group's EV-to-EBIT or its related term are showing as below:
CHIX:AMSl'
s EV-to-EBIT Range Over the Past 10 Years
Min: 12.41 Med: 24.05 Max: 65.74
Current: 29.75
During the past 13 years, the highest EV-to-EBIT of Advanced Medical Solutions Group was 65.74. The lowest was 12.41. And the median was 24.05.
CHIX:AMSl's EV-to-EBIT is ranked worse than 73.33% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.43
vs CHIX:AMSl: 29.75
Advanced Medical Solutions Group (CHIX:AMSl) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Advanced Medical Solutions Group's Enterprise Value for the quarter that ended in Dec. 2025 was £539.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £22.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group EV-to-EBIT Related Terms
Advanced Medical Solutions Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMSL vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's EV-to-EBIT falls into.
Advanced Medical Solutions Group's current Enterprise Value is £671.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £22.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a EV-to-EBIT of 29.75 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Advanced Medical Solutions Group and its competitors. This is 24% above median its historical median of 24.05. Over the past decade, Advanced Medical Solutions Group's EV-to-EBIT has ranged from 12.41 to 65.74. According to the industry distribution chart, Advanced Medical Solutions Group ranks #341 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 73.3%.
Is Advanced Medical Solutions Group's EV-to-EBIT too high?
Advanced Medical Solutions Group's current EV-to-EBIT of 29.75 is 24% above median its 10-year median of 24.05. Over the past 10 years, this metric has ranged from a low of 12.41 to a high of 65.74. The Medical Devices & Instruments industry median EV-to-EBIT is 18.43. Advanced Medical Solutions Group's value of 29.75 is 61.4% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #341 out of 465 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #341 out of 465 companies for EV-to-EBIT. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median EV-to-EBIT is 18.43. Advanced Medical Solutions Group's value of 29.75 is 61.4% above this benchmark. Historically, Advanced Medical Solutions Group's own EV-to-EBIT has ranged from 12.41 to 65.74 over the past decade. While the company's 10-year median is 24.05 vs. the industry median of 18.43, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.43, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current EV-to-EBIT of 29.75 is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current EV-to-EBIT is 29.75, which is 24% above median its own 10-year median of 24.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.72, compared to a current price of £2.80 — trading 24.9% below its estimated fair value. The current EV-to-EBIT is 29.75, which is 24% above median its 10-year median of 24.05 and 61.4% above the Medical Devices & Instruments industry median of 18.43. Advanced Medical Solutions Group's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current EV-to-EBIT is 29.75 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.80 is trading 24.9% below its estimated GF Value™ of £3.72.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
EV-to-EBIT: 29.75 (24% above median its 10-year median of 24.05)
GF Value™: £3.72 vs. price of £2.80 (24.9% below fair value)
Industry Position: 61.4% above the Medical Devices & Instruments median (#341 of 465)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
92GF Score
Get the complete analysis for CHIX:AMSL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
